1 / 55

Cholesterol: The Expanded Lipid Profile

Cholesterol: The Expanded Lipid Profile. Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H. Outline. What is the expanded lipid panel? Why order it? How to order it? What to do with results? Cases Questions. Cases.

jared
Download Presentation

Cholesterol: The Expanded Lipid Profile

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cholesterol:The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H

  2. Outline • What is the expanded lipid panel? • Why order it? • How to order it? • What to do with results? • Cases • Questions

  3. Cases • 54 y/o woman with no risk factors and an LDL of 189. She does not want meds. • 35 y/o Latino male with new onset DM and a “perfect” lipid panel. • 40 y/o male who comes in and tells you that his Dad and brother both had their first MI at 45y/o. His lipids look more or less normal. • Bonus Case from Wendy • A 72 y/o woman obese, HTN, IGT, depression. What is my risk of heart disease or stroke?

  4. Why bother with more? • Not all lipids are the same risk: • impact of LDL size & number • HDL subtypes • In selected patients: Other Risk Factors missed with typical lipid panel • Lp(a) • hsCRP • FHx early CADz and close to normal lipids • Metabolic Syndrome and need more info to change • High Lipids and wants to avoid statins or difficulty tolerating

  5. Question? In addition to the standard lipid profile, What is included in the expanded lipid panel? • LDL subtypes (apoB) • HDL subtypes (2 and 3) • LPa • hsCRP • Homocysteine • All of the above • It depends

  6. What is there and How to Order?

  7. Expanded Lipid Profiles • Quest: expanded lipid panel (or lipid- or homocyt- with homocysteine) • Lipoprotein Particle Analysis (LPP) Spectracell • Berkeley HeartLab (BHL) • NMR: Liposcience • VAP: Atherotec • Hunter: Cardiovascular Risk/Metabolic Syndrome

  8. LDL: particle size and number Less is more (better) ApoB ( one per particle) scientifically accepted measurement for LDL particle number. Can be used to Monitor statintherapy. Bigger is Better • Small LDL is the bad guy why? • it goes across the endothelium more readily • absorbed by macrophages more readily = foam cells…bad

  9. Apo B (LDL pattern) Nl <60

  10. Small LDL= pattern B

  11. Case 1 According to ATP 3 Guidelines what would you recommend for our 54 y/o woman with no risk factors and an LDL of 189? • Life style with a goal of LDL 160 • Life style with a goal of LDL 130 • Start a Statin • Start Bile Acid Binder or Niacin

  12. Case 1 According to ATP 3 Guidelines what would you recommend for our 54 y/o woman with no risk factors and an LDL of 189? • Life style with a goal of LDL 160 • Life style with a goal of LDL 130 • Start a Statin • Start Bile Acid Binder or Niacin

  13. ATP 3 Guidelines-surprisingly generous Google: ATP 3 Guidelines at a glance

  14. ATP3 Guidelines Step 3:risk factors

  15. Her expanded panel results • LDL=189, TG=102, HDL =63 • apoB 20 (low) • hsCRP 0.5 (normal) • HDL2 (normal) • HDL3 (normal) • Lp(a) low • Later an AIC was 5.0 What if her Apo B or hsCRP or AIC was high?

  16. Treatment of small dense LDL Treat LDL cholesterol and think Metabolic or Inflammation • Insulin Resistance (glycocylation) • Check AIC and treat accordingly • Note: I start metformin early in someone who does not make LS changes easily (provider choice). • Inflammation (oxidation) • Check hsCRP • Think of antioxidants • Will cover with hsCRP

  17. HDL HDL 3 Smaller less protective (signal of inefficient transport) HDL 2 (a and b) • Again bigger is better • Reverse cholesterol transport • Antioxidant effect • Increases with exercise, fish oil, niacin, fibric acid, statin and niacin combo’s, moderate alcohol consumption.

  18. Case 2 35 y/o Latino male with new onset DM and a “perfect” lipid panel. • TC 168 • HDL 41 • TG 115 • LDL 104 Expanded Panel • Apo B high • HDL 2 low/3 normal • Hs CRP 1.7 • Lp(a) normal What would you do?

  19. Treatment of Low HDL 2 • Exercise • Niacin • Moderate alcohol consumption (both 2 and 3) • Stop smoking • ?Fish oil • ?statin, FibricAcids, Bile acid binder might start for high apoB • Mediterranean Diet, fish oils, consider probiotic for his high CRP

  20. LipoProtein (a) Niacin NAC 600 mg twice daily Treatment options: • Lp(a) is an inherited abnormal protein attached to LDL. • Normal level < 30 mg/dL • Lp(a) increases coagulation and triples CVD risk.

  21. Case 3 • 40 y/o male who comes in and tells you that his Dad and brother both had their first MI at 45y/o. His lipids look more or less normal. Expanded panel results • Lp(a) high (104) • Others normal What would you do?

  22. Lp(a)

  23. Bonus case: Wendy’s patient • 58 yo woman, slender, healthy eater with h/o ischemic stroke age 58. Year later, ischemic bowel.

  24. Inflammation Lp-PLA2 Slightly more specific for vascular inflammation Low risk <200 mg/ml Hs-CRP • Inflammatory marker • Better then ESR and leucocytes for predicting vascular events • Low Risk level < 1.0 mg/L

  25. hsCRP

  26. Treatment of increased hsCRP • Look for cause: inflammation, infection, trauma. • Consider checking Lp-PLA2 (endothelial inflammation) • Anti-inflammatory regimen • Diet (Mediterranean anti-inflammatory or mod elim) • Exercise (any is better) • Fish oils (dose by EPA/DHA 2-6g a day) • Probiotics (10 billion org a day) • Vit D (check level and treat to 50) • Decrease Stress and support good sleep (cortisol)

  27. 4th Patient • 72 y/o woman obese, HTN, IGT, depression. • “What is my risk of heart disease or stroke?” • How do you answer this question? • Very Concrete thinker • Can you do it in a way that furthers the patients motivation to change and is affordable?

  28. Thoughts after test Routine lipid panel • At Goal • HDL = 65 • VLDL = 18 • Chol/HDL ratio =3.2 • TG’s = 90 • moderate risk • TC = 211 • LDL = 128 • Non-HDL chol = 146 Advanced Risk Markers • High Risk • hsCRP = 4.88 [<1] • sd-LDL = 36.2 [20] • Moderate Risk • Apo B 113 [<60] • Homocysteine 11.2 (<10) At Goal • Lp-PLA2 185.4 (<200)

  29. How to treat • NCEP –ATC diet with goal of dropping 5-10% weight • Lower carbohydrate, higher fiber diet • Omega 3 fats; substitute olive oil • Screen for DM, hypothyroidism • Lower LDL*

  30. ECW tricks: 3 other tests you may want…

  31. Summary • High apoB = Small dense LDL ~ metabolic syndrome • check AIC, treat LDL earlier, LS changes, consider earlier metformin, check hsCRP • Low HDL (especially low High HDL 2) • Exercise, Niacin, moderate ETOH • High Lp(a) bad • Niacin, NAC • High hsCRP (cardio CRP) > 1.0 • r/o infection, inflammation, trauma. Repeat test/ck lp-PLA2 • Anti-inflam regimen (diet, ex, stress, fish oil, probiotic, antioxidants) • Homocysteine: a definite risk factor, interventions lower it, ?if that makes a difference unless they have the condition hyperhomocysteinuria (rare).

  32. Homocysteine • Methylation (if high also check B12/folate/methylmalonic acid) • Functions primarily to protect DNA • How to help • For most Mediterranean Diet adequate, if still a problem may need supplementation • B6 25 micrograms/d • B12 1000micrograms/d • Folate 800micrograms/d (may need as methyl THF)

  33. Progression of Drug Therapy in Primary Prevention If LDL goal not achieved, intensify drug therapy or refer to a lipid specialist If LDL goal not achieved, intensifyLDL-lowering therapy Monitor response and adherence to therapy Initiate LDL-lowering drug therapy 6 wks 6 wks Q 4-6 mo • If LDL goal achieved, treat other lipid risk factors • Start statin or bile acid sequestrant or nicotinic acid • Consider higher dose of statin or add a bile acid sequestrant or nicotinic acid

  34. Lipids Background Cholesterol Functions • Plasma Membranes • Myelinated structures in the CNS • Inner Mitochondrial Membranes • Bile Acids • Steroid Hormones and Sex Hormones • Ergosterol(UV skin) Vit D3

  35. Lipids Background Lipids in Atherosclerosis Dys-Function • Endothelium and damage • LDL and Macrophages • Oxidized LDL and Foam Cells • Also glycosylated and acetylated LDL • Plaque and rupture • HDL as scavenger

  36. Cholesterol General Total Cholesterol/HDL ratio (TC/HDL) Best Lipid predictor of CHD in Framingham Study TC/HDL ratio 1 unit =  CHD risk by 60% Eg TC/HDL ratio of <4 is normal 6 = 120% increased risk 3 = 60% decreased risk

  37. Risk for coronary disease was associated with higher values of • non–HDL-C and LDL-C, • higher ratios of non–HDL-C/HDL-C • apo B/A1 (LDL/HDL) • lower values of HDL-C. • not associated with triglyceride levels • No difference in risk prediction was observed between fasting and non-fasting measurements. JAMA: 2009 68 Studies: 300,000 patients Mean fu 6 years Risk for coronary disease was associated with higher values of non–HDL-C and LDL-C, higher ratios of non–HDL-C/HDL-C apoB/A1 lower values of HDL-C. not associated with triglyceride levels No difference in risk prediction was observed between fasting and nonfasting measurements. Di Angelantonio E et al. for the Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 Nov 11; 302:1993.

  38. IM4U Treatment Pyramid Environment Relationships Resources

  39. IM4U Treatment Pyramid (expanded) Environment Relationships Resources

  40. Drug Therapy 1) HMG CoA Reductase Inhibitors (Statins) • Reduce LDL-C 18–55% & TG 7–30% • Raise HDL-C 5–15% • Major side effects • Myopathy • Increased liver enzymes • Contraindications • Absolute: liver disease • Relative: use with certain drugs

  41. HMG CoA Reductase Inhibitors (Statins) (continued) Demonstrated Therapeutic Benefits • Reduce major coronary events • Reduce CHD mortality • Reduce coronary procedures (PTCA/CABG) • Reduce stroke • Reduce total mortality

  42. Statins: Drug-Nutrient Side Effects Nutrients Depleted • Coenzyme Q10: Statins inhibit the enzyme HMG CoA reductase that is required to make cholesterol and Coenzyme Q10. • Could explain myalgia, exercise intolerance, myoglobuinuria • Also, Selenium, Zinc, Copper • Lower serum PUFA’s and alter the relative % of omega 6:3 fats Arch Neurol 2004;61(6):889 Nutr Metab Cardiovasc Dis 2005; 15(1): 36

  43. Drug Therapy 2) Bile Acid Sequestrants Ex: cholestyramine, colestipol, colesevelam • Major actions • Reduce LDL-C 15–30% • Raise HDL-C 3–5% • May increase TG • Contraindications • Dysbetalipoproteinemia • Raised TG (especially >400 mg/dL)

  44. Bile Acid Sequestrants (continued) • Demonstrated Therapeutic Benefits • Reduce major coronary events • Reduce CHD mortality • Side effects • GI distress/constipation • Decreased absorption of other drugs • Decreases beta-carotene, calcium, folate, Fe, Mg, Vit B12, D, E, K & zinc (cholestyramine)

  45. Drug Therapy 3) Nicotinic Acid • Major actions • Lowers LDL-C 5–25% • Lowers TG 20–50% • Raises HDL-C 15–35% • Side effects: flushing, hyperglycemia, hyperuricemia, upper GI distress, hepatotoxicity • Contraindications: liver disease, severe gout, peptic ulcer

  46. Nicotinic Acid Drug FormDose Range Immediate release 1.5–3 g(crystalline) Extended release 1–2 g Sustained release 1–2 g

  47. Nicotinic Acid (continued) Demonstrated Therapeutic Benefits • Reduces major coronary events • Possible reduction in total mortality

  48. Drug Therapy 4) Fibric Acids Example: gemfibrozil, fenofibrate, clofibrate • Major actions • Lower LDL-C 5–20% (with normal TG) • May raise LDL-C (with high TG) • Lower TG 20–50% • Raise HDL-C 10–20% • Contraindications: Severe renal or hepatic disease

  49. Fibric Acids (continued) • Demonstrated Therapeutic Benefits • Reduce progression of coronary lesions • Reduce major coronary events • Side effects: dyspepsia, gallstones, myopathy • Drug-nutrient interactions: Decrease CoQ10 also, Vitamin E, (fenofibrate incr’s homocysteine)

More Related